Provided by Tiger Fintech (Singapore) Pte. Ltd.

Anaptysbio Inc

23.88
+1.235.43%
Volume:677.81K
Turnover:16.28M
Market Cap:701.61M
PE:-4.98
High:24.69
Open:22.61
Low:22.43
Close:22.65
Loading ...

Director Dennis M. Fenton Reports Disposal of Common Shares of AnaptysBio Inc

Reuters
·
21 Jun

Director Renton Hollings Reports Disposal of Common Shares of AnaptysBio Inc

Reuters
·
21 Jun

AnaptysBio Inc. Conducted Annual Stockholder Meeting

Reuters
·
18 Jun

AnaptysBio shares are undervalued, says JPMorgan

TIPRANKS
·
11 Jun

BUZZ-U.S. STOCKS ON THE MOVE-TransMedics, Centrus Energy,  MongoDB

Reuters
·
05 Jun

Crude Oil Falls Over 1%; ISM Services PMI Tumbles In May

Benzinga
·
05 Jun

Sector Update: Health Care Stocks Mixed Premarket Wednesday

MT Newswires Live
·
04 Jun

BUZZ-AnaptysBio rises after H.C. Wainwright upgrades to 'buy' on arthritis drug progress

Reuters
·
04 Jun

AnaptysBio Shares up 2.7% Premarket After H.c. Wainwright Raises to Buy From Neutral

THOMSON REUTERS
·
04 Jun

AnaptysBio (ANAB) Receives a Hold from Truist Financial

TIPRANKS
·
04 Jun

AnaptysBio Raised to Buy From Neutral by HC Wainwright & Co.

Dow Jones
·
04 Jun

HC Wainwright Upgrades AnaptysBio to Buy From Neutral, $38 Price Target

MT Newswires Live
·
04 Jun

AnaptysBio Rise 6% After Results From Rheumatoid Arthritis Treatment Rosnilimab

Dow Jones
·
04 Jun

AnaptysBio announces investigational rosnilimab data

TIPRANKS
·
04 Jun

AnaptysBio Unveils Promising Six-Month Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis, Showcasing JAK-Like Efficacy and Favorable Safety Profile

Reuters
·
04 Jun

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2B Trial in Ra

THOMSON REUTERS
·
04 Jun

AnaptysBio Is Maintained at Buy by Guggenheim

Dow Jones
·
28 May

Anaptys to Announce Updated Data From Phase 2B Trial of Rosnilimab, a Pd-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

THOMSON REUTERS
·
28 May

AnaptysBio Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
07 May

Analysts Conflicted on These Healthcare Names: AnaptysBio (ANAB), Relay Therapeutics (RLAY) and Inspire Medical Systems (INSP)

TIPRANKS
·
07 May